$LLY vs. $NVO: What's the Better Weight-Loss Stock to Buy?

$Novo-Nordisk A/S(NVO)$ appears to be continuing its rapid development.

  • On October 16, 2023, $Novo-Nordisk A/S(NVO)$ announced that it has agreed to acquire ocedurenone, a drug used to control hypertension, from KBP Biosciences for up to $1.3 billion.

  • On 13 October, $Novo-Nordisk A/S(NVO)$ raised its full-year revenue and profit guidance on soaring sales of its weight-loss and diabetes-control drugs Wegovy and Ozempic.

The Danish drugmaker now expects currency-adjusted sales to rise 32% to 38% this year, up from a previous forecast of 27% to 33% $Novo-Nordisk A/S(NVO)$ expects 2023 operating profit growth of 40% to 46%, up from previous guidance of 31% to 37%.

Some colleagues and friends shared that the company's weight-loss drugs are effective. Huge demand for Ozempic and Wegovy has helped $Novo-Nordisk A/S(NVO)$ become Europe's most valuable company.

A Wegovy injectionA Wegovy injection

Since this year, the two drug companies $Eli Lilly(LLY)$ & $Novo-Nordisk A/S(NVO)$ have seen red-hot demand for their weight-loss treatments. The two companies have up more than 60% & 49% this year respectively.

The market value of $Eli Lilly(LLY)$ once rose into the top 10 of the U.S. stock market (currently ranked 12th with a market value of $554.54B).

The market value of $Novo-Nordisk A/S(NVO)$ (current rank 16 with a market value of $452.27B) also overtook luxury goods giant LVMH Group in September to become the company with the highest market value in Europe.


Question for Tigers:

1. Do you or your friend have experienced using this medicine?

2. Which is the better weight-loss stock to invest in today? $Novo-Nordisk A/S(NVO)$ & $Eli Lilly(LLY)$ ?

3. Are there any other drug companies that will also benefit from the weigh loss market?

For more information, welcome read:

@WallStreet_Tiger , Healthcare Stocks Continue to Hit Records: LLY, AFL, MCK

@MillionaireTiger , LVMH's Steep Descent: Novo Emerges as Europe's Largest Company

@JinHan , Wegovy and Novo Nordisk: Riding the Wave of Health-Conscious Lifestyles

@Ryan_Z0528 , $NVO's Market Value is Close to $TSLA. Will You Buy it Now?

@Trend_Radar , 🎁 $LLY & $NVO Hit All Time High, Buy High and Sell Higher?

# 💰Stocks to watch today?(26 Dec)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment14

  • Top
  • Latest
  • Shyon
    ·2023-10-18
    TOP

    Personally, I think both $Eli Lilly(LLY)$ and $Novo-Nordisk A/S(NVO)$ are good choice among the drug companies. Being the global healthcare leaders, and with a focus on diabetes care, both companies have demonstrated impressive financial stability over the years. Their consistent revenue growth and strong R&D investments underscore their commitment to innovation! Well, there's no any friend around me consume these medicine currently. Haha!

    @koolgal @rL @Universe宇宙 @icycrystal @b1uesky @Aqa @GoodLife99 

    Reply
    Report
    Fold Replies
    View more 4 comments
  • Aqa
    ·2023-10-19
    Huge demand for FDA-approved Ozempic and Wegovy (both anti-obesity medications) has helped $Novo-Nordisk A/S(NVO)$ become Europe's most valuable company.. Tesla CEO Elon Musk, Rosie O’Donnell and Amy Schumerall have used the medication and “singing the drug’s praises “. America listed company $Eli Lilly(LLY)$ is also very successful for weight-loss treatments. Both stocks have up mirr than 49% and 60% this year. Thanks [love you] @Shyon [love you]
    Reply
    Report
  • Universe宇宙
    ·2023-10-18
    @TigerGPT perform fundamental analysis on NVO and LLY and compare.
    Reply
    Report
    Fold Replies
    • TigerAI

      Based on the information provided, I cannot answer the first question about personal experiences with Novo Nordisk's weight-loss medicine as I don't have access to personal experiences or opinions.

      Regarding the second question, it is difficult to determine which stock is better to invest in without considering various factors such as financial performance, market conditions, and future prospects. However, based on the information provided, Eli Lilly has shown positive growth in Q2 2023 with a 22% increase in revenue and strong performance in new products and growth categories. On the other hand, Novo Nordisk's recent stock performance has been mixed, with a slight decline in the latest trading session. It is recommended to conduct further research and analysis before making any investment decisions.

      As for the third question, there may be other drug companies that could benefit from the weight loss market. However, the provided information does not specifically mention any other companies in this context. It would be advisable to explore the market and industry trends to identify potential competitors or companies focusing on weight loss medications.

      Reference articles:

      Novo Nordisk (NVO) to Acquire Hypertension Drug for $1.3B  

      $LLY vs. $NVO: What's the Better Weight-Loss Stock to Buy?  

      Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know  

      Wegovy and Novo Nordisk: Riding the Wave of Health-Conscious Lifestyles  

      2023-10-18
      Reply
      Report
  • Universe宇宙
    ·2023-10-18
    @TigerGPT perform technical analysis on NVO and LLY and compare.
    Reply
    Report
    Fold Replies
    • TigerAI

      Based on the information provided, both Novo-Nordisk A/S (NVO) and Eli Lilly (LLY) are pharmaceutical companies that have potential in the weight-loss market.

      Regarding Novo-Nordisk A/S, the target price estimates from analysts range from $58.0 to $105.0, with a mean estimate of $80.10973. The latest price of Novo-Nordisk A/S is $100.885. The stock has shown a bullish trend recently, with a profiteer ratio of 0.884. In terms of capital flow, there has been a big inflow of $1.31M in the past day. However, there is no specific news available about Novo-Nordisk A/S related to weight-loss.

      As for Eli Lilly, the target price estimates from analysts range from $340.0 to $700.0, with a mean estimate of $589.82083. The latest price of Eli Lilly is $613.3255. The stock has also shown a bullish trend recently, with a profiteer ratio of 0.9682. In terms of capital flow, there has been a big inflow of $4.01M in the past day. Similar to Novo-Nordisk A/S, there is no specific news available about Eli Lilly related to weight-loss.

      Based on the information provided, both Novo-Nordisk A/S and Eli Lilly have positive analyst recommendations and show a bullish trend. However, it is important to conduct further research and analysis before making any investment decisions. It is also worth considering other drug companies that may benefit from the weight-loss market.

      Reference articles:

      Novo Nordisk (NVO) to Acquire Hypertension Drug for $1.3B  

      $LLY vs. $NVO: What's the Better Weight-Loss Stock to Buy?  

      Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know  

      $NVO's Market Value is Close to $TSLA. Will You Buy it Now?  

      Wegovy and Novo Nordisk: Riding the Wave of Health-Conscious Lifestyles  

      2023-10-18
      Reply
      Report
  • highhand
    ·2023-10-18
    neither. you must eat less, as and exercise to lose weight. not take drugs. [Happy]
    Reply
    Report